NASDAQ:TGTXTG Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TG Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.28 +0.69 (+3.92 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$18.07Now: $18.28▼$19.5350-Day Range$10.32MA: $16.63▼$21.8452-Week Range$4.95Now: $18.28▼$22.28Volume2.93 million shsAverage Volume2.32 million shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/ABeta2.45 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTG Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, TG Therapeutics has a potential upside of 124.3% from its current price of $18.28.Amount of Analyst CoverageTG Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesTG Therapeutics has received 582 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTG Therapeutics has received 306 “underperform” votes. (Add your “underperform” vote.)Community SentimentTG Therapeutics has received 65.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote “Outperform” if you believe TGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTG Therapeutics does not currently pay a dividend.Dividend GrowthTG Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TG Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.20% of the stock of TG Therapeutics is held by insiders.Percentage Held by Institutions58.88% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TG Therapeutics are expected to grow in the coming year, from ($1.46) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TG Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TG Therapeutics is -9.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTG Therapeutics has a P/B Ratio of 46.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TGTX Previous Symbol CUSIPN/A CIK1001316 Webwww.tgtherapeutics.com Phone212-554-4484Debt Debt-to-Equity Ratio1.01 Current Ratio1.39 Quick Ratio1.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales13,426.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book46.87Profitability EPS (Most Recent Fiscal Year)($1.83) Net Income$-172,870,000.00 Net Margins-124,230.27% Return on Equity-2,937.74% Return on Assets-155.97%Miscellaneous Employees105 Outstanding Shares110,170,000Market Cap$2.01 billion Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:TGTX Rates by TradingView Receive TGTX News and Ratings via Email Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions How has TG Therapeutics' stock been impacted by COVID-19 (Coronavirus)? TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX shares have increased by 82.6% and is now trading at $18.28. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TG Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TG Therapeutics. When is TG Therapeutics' next earnings date? TG Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for TG Therapeutics. How were TG Therapeutics' earnings last quarter? TG Therapeutics Inc (NASDAQ:TGTX) announced its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.12. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 124,230.27% and a negative return on equity of 2,937.74%. View TG Therapeutics' earnings history. What price target have analysts set for TGTX? 4 Wall Street analysts have issued 1-year price objectives for TG Therapeutics' stock. Their forecasts range from $32.00 to $60.00. On average, they anticipate TG Therapeutics' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 124.3% from the stock's current price. View analysts' price targets for TG Therapeutics. Has TG Therapeutics been receiving favorable news coverage? News stories about TGTX stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TG Therapeutics earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutTG Therapeutics. Who are some of TG Therapeutics' key competitors? Some companies that are related to TG Therapeutics include Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Mirati Therapeutics (MRTX) and PPD (SDGR). View all competitors. What other stocks do shareholders of TG Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Amarin (AMRN), UrtheCast (UR), Gilead Sciences (GILD), BioDelivery Sciences International (BDSI), AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA) and Synergy Pharmaceuticals (SGYP). Who are TG Therapeutics' key executives? TG Therapeutics' management team includes the following people: Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. CommunicationsMr. Adam Waldman, Chief Commercial Officer What is TG Therapeutics' stock symbol? TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX." Who are TG Therapeutics' major shareholders? TG Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.43%), BlackRock Inc. (5.58%), State Street Corp (3.17%), Geode Capital Management LLC (1.22%), Lord Abbett & CO. LLC (0.86%) and Nuveen Asset Management LLC (0.57%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy. View institutional ownership trends for TG Therapeutics. Which institutional investors are selling TG Therapeutics stock? TGTX stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Rafferty Asset Management LLC, JPMorgan Chase & Co., Raymond James & Associates, Wells Fargo & Company MN, Frontier Wealth Management LLC, HighTower Advisors LLC, and Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for TG Therapeutics. Which institutional investors are buying TG Therapeutics stock? TGTX stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RA Capital Management L.P., Nuveen Asset Management LLC, Geode Capital Management LLC, Ghost Tree Capital LLC, Federated Hermes Inc., State Street Corp, and BlackRock Inc.. View insider buying and selling activity for TG Therapeutics. How do I buy shares of TG Therapeutics? Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TG Therapeutics' stock price today? One share of TGTX stock can currently be purchased for approximately $18.28. How big of a company is TG Therapeutics? TG Therapeutics has a market capitalization of $2.01 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 105 workers across the globe. What is TG Therapeutics' official website? The official website for TG Therapeutics is www.tgtherapeutics.com. How can I contact TG Therapeutics? TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
